AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab - Report - MDSpire
Advertisement
AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab
Clinical Report: Prognostic Value of AAT Score in Unresectable HCC Patients
Overview
This study developed the AAT score model to predict overall survival in patients with unresectable hepatocellular carcinoma (uHCC) undergoing TACE combined with sintilimab and bevacizumab therapy. The model demonstrated significant prognostic value, stratifying patients into distinct risk groups based on their pre-treatment factors.
Background
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, particularly in China, where most patients present with advanced disease. The combination of transarterial chemoembolization (TACE) with systemic therapies like sintilimab and bevacizumab has shown promise in improving outcomes for these patients. Identifying effective prognostic tools is crucial for optimizing treatment strategies and improving survival rates.
Data Highlights
Risk Group
2-Year OS Rate
2-Year PFS Rate
Low (≤1.8)
80.0%
63.3%
Median (>1.8 to ≤3.0)
48.0%
56.0%
High (>3.0)
4.0%
4.0%
Key Findings
The AAT score model incorporates alpha-fetoprotein (AFP), alkaline phosphatase (ALP), and tumor burden score (TBS) as independent predictors of overall survival.
The model achieved areas under the ROC curve of 0.813 and 0.819 in training and validation cohorts, respectively.
Kaplan-Meier analysis demonstrated significant stratification of patients into low, median, and high-risk groups based on AAT scores.
Patients in the low-risk group had a 2-year overall survival rate of 80.0%, compared to only 4.0% in the high-risk group.
The AAT score can guide personalized treatment decisions for uHCC patients undergoing combination therapy.
Clinical Implications
The AAT score model provides a valuable tool for clinicians to stratify patients with uHCC based on their prognosis, facilitating more tailored treatment approaches. By identifying patients at higher risk of poor outcomes, healthcare providers can optimize therapy and potentially improve survival rates.
Conclusion
The AAT score model effectively stratifies overall survival and progression-free survival in patients with unresectable HCC undergoing TACE combined with sintilimab and bevacizumab, supporting its use in clinical decision-making.
